The mass spectrometry-based test is intended as an aid in evaluating individuals with signs of cognitive impairment for the amyloid brain pathology associated with Alzheimer's.

HealthTab will distribute Abbott's Afinion 2 Analyzer in National Health Service-linked pharmacies to test for HbA1c and lipid profiles.

The firm recently raised $15 million in seed financing to further validate and commercialize its pathogen detection and antimicrobial resistance profiling platform.

Analysts for the banks noted the large addressable market for the company's cancer screening tests as well as the benefits of its commercialization deals with Abbott and Roche.

There was a noticeable uptick in digital pathology devices and software clearances among more than a dozen 510(k)s granted by the agency last month.

The clearances include one for an AI-assisted quality control software that detects six common whole-slide image artifacts.

LisenID uses a biomarker called loss of imprinting to apply to ambiguous biopsy results and return a diagnosis of lung cancer.

Natera's tissue-free assay Latitude will be used in Kupando's clinical trial of its lead immunotherapy candidate KUP-101.

According to CEO Wesley Sukdao, Proteotype is also gearing up to raise about £5 million and seeking a lead investor.

An analyst with investment bank Leerink partners noted that Freenome is addressing a significant total addressable market in liquid biopsy cancer screening.